title: Elution and mechanical properties of antifungal bone cement.
abstract: The effect of the incorporation of amphotericin B into bone cement was examined; as literature suggests, this may be a feasible method for the treatment of periprosthetic fungal infections. Addition of antifungal increased the compressive strength of the bone cement--a statistically significant amount from 107 +/- 2.3 to 121 +/- 1.5 MPa. Elution of tobramycin and amphotericin B was quantified using ultraviolet-visible spectroscopy. Spectroscopy showed that 18% of the antibiotic was released during the first week, with most released in the first 24 hours. The elution of antifungal, however, was unable to be detected after 1 week, with less than 0.03% released. Amphotericin B does not weaken bone cement. Its inability to be delivered at a clinically significant dose gives no clear indication for its incorporation into cement.
authors.affiliation: AO Spine Reference Centre, Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Australia.
authors.forename: Ben
authors.initials: B
authors.lastname: Goss
authors.forename: Carmen
authors.initials: C
authors.lastname: Lutton
authors.forename: Patrick
authors.initials: P
authors.lastname: Weinrauch
authors.forename: Majid
authors.initials: M
authors.lastname: Jabur
authors.forename: Greg
authors.initials: G
authors.lastname: Gillett
authors.forename: Ross
authors.initials: R
authors.lastname: Crawford
mesh_terms: D000666:Amphotericin B / Q000008:administration & dosage*; D000900:Anti-Bacterial Agents / Q000008:administration & dosage; D000935:Antifungal Agents / Q000008:administration & dosage*; D001843:Bone Cements; D006801:Humans; D009181:Mycoses / Q000517:prevention & control*; D016459:Prosthesis-Related Infections / Q000517:prevention & control*; D013057:Spectrum Analysis; D014031:Tobramycin / Q000008:administration & dosage